OLMA241220C15000
- 0.75
- 0.000.00%
Olema Pharmaceuticals Newsroom
J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)
Express News | Olema Pharmaceuticals Inc : JP Morgan Cuts Target Price to $29 From $31
A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $29 to $30
Optimistic Outlook for Olema Pharmaceuticals: Promising Clinical Data and Strategic Pipeline Developments
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Olema Pharmaceuticals | 8-K: Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Olema Pharmaceuticals 3Q Loss/Shr 60c >OLMA
Express News | Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Olema Oncology Q3 Net Income USD -34.555 Million
Olema Oncology to Participate in Upcoming Investor Conferences
Express News | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Olema Pharmaceuticals Insiders Sell US$1.6m Of Stock, Possibly Signalling Caution
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $29
Capital One Financial Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $26
Promising Potential of Olema Pharmaceuticals' Palazestrant and KAT6 Inhibitor Fuels Buy Rating
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
Buy Rating for Olema Pharmaceuticals: Promising Preclinical Data and Strategic Pipeline Synergy
Express News | Olema Oncology Highlights Presentation Of Preclinical Data Demonstrating Anti-Tumor Activity For OP-3136